GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity)

The GLP-1 Analogues market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period. The key factors driving the growth of the GLP-1 Analogues market include the growing popularity of the GLP-1 drug class for the treatment of chronic obesity and weight management and high efficacy of GLP-1 analogues for treating type 2 diabetes. Additionally, innovation focusing on the development of convenient forms of GLP-1 drugs, such as oral dosage forms and single dose autoinjectors, are expected to drive growth of GLP-1 analogues market. The GLP-1 Analogues market has been segmented based on products, format, route of administration, indication, and end-user.

By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market

Based on product, the GLP-1 Analogues market is categorized into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. Zepbound is expected to experience fastest growth during the forecast period owing to factors such as approval of the drug for the treatment of obesity, exponential revenue growth observed since launch of the drug in 2023, and growing adoption of tirzepatide for obesity and weight management.

By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market

Based on product format, the GLP-1 Analogues market is segmented into single-dose, multi-dose, and tablets. In 2023, the single-dose format segment accounted for the largest share of the GLP-1 Analogues market. Growth in this market segment can be attributed to the ease of administration and lower injection frequencies offered by single-dose format, together with the growing availability of single-dose auto-injectors.

North America: accounted for the largest share of the GLP-1 Analogues market

North America accounted for the largest share of the GLP-1 Analogues market. The large share of the North American region can be attributed to growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of GLP-1 products in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include Eli Lilly and Company (US), Novo Nordisk A/S (Denmark).

Europe: The second-largest region in the GLP-1 Analogues market

The Europe GLP-1 Analogues market is the second largest market for GLP-1 Analogue drugs. This is attributed to the presence of a large number of academic and research institutes in this region, growing investments by market players and government institutes, and an increasing focus on research and development activities.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side - 70% and Demand Side 30%
By Designation: Managers - 45%, Directors - 30%, and Executives - 25%
By Country: North America - 40%, Europe - 30%, Asia Pacific - 20%, Latin America - 5%, and Middle East and Africa - 5%

Prominent Players

Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China), Boehringer Ingelheim International GmbH (Germany), Innovent (China), Paige Biopharmaceutical (Suzhou) Co., Ltd. (China), Sciwind Biosciences Co., Ltd. (China), Zealand Pharma A/S (Denmark), Beijing Dongfang Baitai Biotechnology Co., Ltd (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China).

Research Coverage

This report provides a detailed picture of the GLP-1 Analogues market. It aims to estimate the size and future growth potential of the market across different segments, such as the product, product format, route of administration, indication, end user, and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the GLP-1 Analogues market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provides insights on the following pointers

Analysis of key drivers (Strong R&D pipeline, Improved relative efficacy of GLP-1 drugs), opportunities (Integration of GLP-1 drugs into telehealth and digital weight management programs), restraints (High barriers for new entrants due to duopoly), and challenges (Off-label use of GLP-1 drugs, High non-adherence to therapy after 12-24 months) influencing the growth of the GLP-1 Analogues market.
Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the GLP-1 Analogues market.
Market Development: Comprehensive information about lucrative markets- the report analyses the GLP-1 Analogues market across varied regions.
Market Diversification: Exhaustive information about new drugs, untapped geographies, recent developments, and investments in the GLP-1 Analogues market.
Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

1 Introduction

1.1 Study Objectives
1.2 Market Definition
1.2.1 Inclusions & Exclusions
1.3 Market Scope
1.3.1 Markets Covered
Figure 1 Glp-1 Analogues Market Segmentation
1.3.2 Regions Covered
Figure 2 Glp-1 Analogues Industry: Regional Segmentation
1.3.3 Years Considered
1.3.4 Currency Considered
1.4 Stakeholders
1.5 Recession Impact

2 Research Methodology

2.1 Research Data
Figure 3 Research Design
2.1.1 Secondary Data
2.1.2 Primary Data
Figure 4 Breakdown of Primaries: Supply- and Demand-Side Participants
2.2 Market Size Estimation
Figure 5 Market Size Estimation: Supply-Side Analysis, 2023
Figure 6 Market Size Estimation: Approach 1 (Revenue Share Analysis), 2023
Figure 7 Market Validation from Primary Experts
2.2.1 Market Size Assessment
Figure 8 Market Size Estimation: Bottom-Up Approach
2.3 Market Growth Forecast
Figure 9 CAGR Projections: Glp-1 Analogues Market, 2024-2032
Figure 10 Growth Analysis of Drivers, Restraints, Opportunities, and Challenges in Glp-1 Analogues Industry
2.4 Market Breakdown & Data Triangulation
Figure 11 Data Triangulation Methodology
2.5 Study Assumptions
2.6 Limitations
2.7 Risk Analysis
2.8 Recession Impact Analysis
Table 1 US Health Expenditure, 2023-2030 (USD Million)

3 Executive Summary

Figure 12 Glp-1 Analogues Market, by Product, 2024 vs. 2032 (USD Billion)
Figure 13 Glp-1 Analogues Industry Share, by Format, 2024 vs. 2032 (USD Billion)
Figure 14 Market Share, by Route of Administration, 2024 vs. 2032 (USD Billion)
Figure 15 Market Share, by Indication, 2024 vs. 2032 (USD Billion)
Figure 16 Market, by End-user, 2024-2032 (USD Billion)
Figure 17 Market: Geographical Snapshot

4 Premium Insights

4.1 Glp-1 Analogues Market Overview
Figure 18 Improved Efficacy of Glp-1 Drugs to Drive Market Growth
4.2 North America: Glp-1 Analogues Industry Share, by Indication and Country (2023)
Figure 19 Diabetes Segment Accounted for Largest Share of North American Market in 2023
4.3 Market Share, by Product, 2024 vs. 2032
Figure 20 Ozempic to Dominate Market in 2032
4.4 Market Share, by Indication, 2023
Figure 21 Diabetes Indications to Account for Largest Market Share in 2023
4.5 Market Share, by End-user, 2024 vs. 2032
Figure 22 Home Care Settings to Dominate the Market in 2032
4.6 Market: Geographic Growth Opportunities
Figure 23 US to Witness Highest Growth During Forecast Period

5 Market Overview

5.1 Introduction
5.2 Market Dynamics
Figure 24 Glp-1 Analogues Market: Drivers, Restraints, Opportunities, and Challenges
Table 2 Glp-1 Analogues Industry: Impact Analysis
5.2.1 Drivers
5.2.1.1 Strong R&D Pipeline
5.2.1.2 Improved Relative Efficacy of Glp-1 Drugs
5.2.1.3 High Demand, Expanding Insurance Coverage, Growing Sales, Increasing Awareness, and Positive Outcomes
5.2.2 Restraints
5.2.2.1 High Barriers for New Entrants due to Duopoly
5.2.3 Opportunities
5.2.3.1 Extended Therapeutic Uses
Figure 25 US: Prevalence of Indications That May Respond to Glp-1 Drugs (As of January 2024)
5.2.3.2 Integration of Glp-1 Drugs into Telehealth and Digital Weight Management Programs
5.2.4 Challenges
5.2.4.1 Off-Label Use of Glp-1 Drugs
5.2.4.2 High Non-Adherence to Therapy After 12-24 Months
5.3 Trends/Disruptions Impacting Customers’ Businesses
Figure 26 Revenue Shift in Market
5.4 Pricing Analysis
5.4.1 Average Selling Price Trend of Glp-1 Analogues
Figure 27 Average Selling Price Trend, by Product
5.4.2 Average Selling Prices of Top Glp-1 Analogues, by Country/Region
Table 3 Average Selling Price Range of Top Glp-1 Analogues (2023-2024)
Figure 28 Product Pricing, by Country (2023-2024)
5.5 Technology Analysis
5.5.1 Key Technologies
5.5.1.1 Chemical Synthesis
5.5.1.2 Recombinant DNA Technology
5.5.2 Adjacent Technologies
5.5.2.1 Hydrogel Depot Technology
5.5.2.2 Technologies for Oral Delivery of Glp-1 Analogues
5.6 Pipeline Analysis
Table 4 Glp-1 Analogues in Clinical Pipeline (As of May 2024)
Figure 29 Additional Launches of Glp-1 Drugs, 2025-2032
Figure 30 Phase 3 Pipeline, by Indication
5.7 Trade Data
5.8 Patent Analysis
5.8.1 Methodology
5.8.2 Innovation and Patent Applications
Figure 31 Total Number of Patents Granted, 2014-2024
5.8.3 Top Applicants
Figure 32 Top Ten Players with Highest Number of Patent Applications, 2014-2024
Table 5 Top 20 Patent Owners in Market, 2014-2024
Table 6 Indicative List of Patents in Market, 2022-2024
5.9 Value Chain Analysis
Figure 33 Value Chain Analysis: Product Development and Manufacturing Phase Contributes Maximum Value
5.10 Supply Chain Analysis
Figure 34 Market: Supply Chain Analysis
5.11 Ecosystem Analysis
Figure 35 Market: Ecosystem Analysis
5.11.1 Market: Role of Raw Material Vendors
Table 7 Market: Role of Raw Material Vendors
5.11.2 Market: Role of Product Providers and Phase 3 Pipeline Product Companies
Table 8 Market: Role of Product Providers and Phase 3 Pipeline Product Companies
5.11.3 Market: Role of End-users
Table 9 Market: Role of End-users
5.11.4 Market: Role of Regulatory Authorities
Table 10 Market: Role of Regulatory Authorities
5.12 Porter's Five Forces Analysis
Table 11 Market: Porter's Five Forces Analysis
Figure 36 Market: Porter's Five Forces Analysis
5.12.1 Threat of New Entrants
5.12.2 Threat of Substitutes
5.12.3 Bargaining Power of Suppliers
5.12.4 Bargaining Power of Buyers
5.12.5 Intensity of Competitive Rivalry
5.13 Key Stakeholders and Buying Criteria
5.13.1 Key Stakeholders in Buying Process
Figure 37 Influence of Stakeholders in Buying Process of Glp-1 Analogues, Hospitals
5.13.2 Buying Criteria for Glp-1 Analogues
Figure 38 Key Buying Criteria for End-users
Table 12 Buying Criteria for Glp-1 Analogues, by End-user
5.14 Regulatory Landscape
5.14.1 Regulatory Scenario
5.14.2 Regulatory Bodies, Government Agencies, and Other Organizations
5.14.2.1 North America
Table 13 North America: List of Regulatory Bodies, Government Agencies, and Other Organizations
5.14.2.2 Europe
Table 14 Europe: List of Regulatory Bodies, Government Agencies, and Other Organizations
5.14.2.3 Asia-Pacific
Table 15 Asia-Pacific: List of Regulatory Bodies, Government Agencies, and Other Organizations
5.14.2.4 Rest of the World
Table 16 Rest of the World: List of Regulatory Bodies, Government Agencies, and Other Organizations
5.15 Key Conferences & Events, 2024-2025
Table 17 Market: Detailed List of Conferences & Events, 2024-2025
5.16 Case Studies
5.16.1 Study of Tirzepatide as a Case in Glp-1 Drugs Market
5.16.2 Ozempic Off-Label Use
5.17 Investment and Funding Scenario

6 Glp-1 Analogues Market, by Product

6.1 Introductions
Table 18 Glp-1 Analogues Industry, by Product, 2022-2032 (USD Billion)
Table 19 Market for Anti-Obesity Products (Million Units)
6.2 Ozempic
6.2.1 Rising Adoption to Support Market Growth
Table 20 Ozempic Market, by Region, 2022-2032 (USD Billion)
Table 21 North America: Ozempic Market, by Country, 2022-2032 (USD Billion)
Table 22 Europe: Ozempic Market, by Country, 2022-2032 (USD Billion)
Table 23 Asia-Pacific: Ozempic Market, by Country, 2022-2032 (USD Billion)
Table 24 Latin America: Ozempic Market, by Country, 2022-2032 (USD Billion)
Table 25 Middle East: Ozempic Market, by Region, 2022-2032 (USD Billion)
Table 26 Gcc Countries: Ozempic Market, by Country, 2022-2032 (USD Billion)
6.3 Trulicity
6.3.1 Competitor Revenue Growth to Affect Growth
Table 27 Trulicity Market, by Region, 2022-2032 (USD Billion)
Table 28 North America: Trulicity Market, by Country, 2022-2032 (USD Billion)
Table 29 Europe: Trulicity Market, by Country, 2022-2032 (USD Billion)
Table 30 Asia-Pacific: Trulicity Market, by Country, 2022-2032 (USD Billion)
Table 31 Latin America: Trulicity Market, by Country, 2022-2032 (USD Billion)
Table 32 Middle East: Trulicity Market, by Region, 2022-2032 (USD Billion)
Table 33 Gcc Countries: Trulicity Market, by Country, 2022-2032 (USD Billion)
6.4 Mounjaro
6.4.1 Exponential Growth Anticipated due to High Adoption in North America
Table 34 Mounjaro Market, by Region, 2022-2032 (USD Billion)
Table 35 North America: Mounjaro Market, by Country, 2022-2032 (USD Billion)
Table 36 Europe: Mounjaro Market, by Country, 2022-2032 (USD Billion)
Table 37 Asia-Pacific: Mounjaro Market, by Country, 2022-2032 (USD Billion)
Table 38 Latin America: Mounjaro Market, by Country, 2022-2032 (USD Billion)
Table 39 Middle East: Mounjaro Market, by Region, 2022-2032 (USD Billion)
Table 40 Gcc Countries: Mounjaro Market, by Country, 2022-2032 (USD Billion)
6.5 Wegovy
6.5.1 Increasing Use for Weight Management to Support Growth
Table 41 Wegovy Market, by Region, 2022-2032 (USD Billion)
Table 42 North America: Wegovy Market, by Country, 2022-2032 (USD Billion)
Table 43 Europe: Wegovy Market, by Country, 2022-2032 (USD Billion)
Table 44 Asia-Pacific: Wegovy Market, by Country, 2022-2032 (USD Billion)
Table 45 Latin America: Wegovy Market, by Country, 2022-2032 (USD Billion)
Table 46 Middle East: Wegovy Market, by Region, 2022-2032 (USD Billion)
Table 47 Gcc Countries: Wegovy Market, by Country, 2022-2032 (USD Billion)
6.6 Rybelsus
6.6.1 Convenience of Oral Administration to Drive Market
Table 48 Rybelsus Market, by Region, 2022-2032 (USD Billion)
Table 49 North America: Rybelsus Market, by Country, 2022-2032 (USD Billion)
Table 50 Europe: Rybelsus Market, by Country, 2022-2032 (USD Billion)
Table 51 Asia-Pacific: Rybelsus Market, by Country, 2022-2032 (USD Billion)
Table 52 Latin America: Rybelsus Market, by Country, 2022-2032 (USD Billion)
Table 53 Middle East: Rybelsus Market, by Region, 2022-2032 (USD Billion)
Table 54 Gcc Countries: Rybelsus Market, by Country, 2022-2032 (USD Billion)
6.7 Saxenda
6.7.1 Development of Generic Versions to Slow Growth
Table 55 Saxenda Market, by Region, 2022-2032 (USD Billion)
Table 56 North America: Saxenda Market, by Country, 2022-2032 (USD Billion)
Table 57 Europe: Saxenda Market, by Country, 2022-2032 (USD Billion)
Table 58 Asia-Pacific: Saxenda Market, by Country, 2022-2032 (USD Billion)
Table 59 Latin America: Saxenda Market, by Country, 2022-2032 (USD Billion)
Table 60 Middle East: Saxenda Market, by Region, 2022-2032 (USD Billion)
Table 61 Gcc Countries: Saxenda Market, by Country, 2022-2032 (USD Billion)
6.8 Victoza
6.8.1 Adoption of Oral Glp-1S to Restrain Market Growth
Table 62 Victoza Market, by Region, 2022-2032 (USD Billion)
Table 63 North America: Victoza Market, by Country, 2022-2032 (USD Billion)
Table 64 Europe: Victoza Market, by Country, 2022-2032 (USD Billion)
Table 65 Asia-Pacific: Victoza Market, by Country, 2022-2032 (USD Billion)
Table 66 Latin America: Victoza Market, by Country, 2022-2032 (USD Billion)
Table 67 Middle East: Victoza Market, by Region, 2022-2032 (USD Billion)
Table 68 Gcc Countries: Victoza Market, by Country, 2022-2032 (USD Billion)
6.9 Xultophy
6.9.1 Regulatory Approvals to Support Market Growth
Table 69 Xultophy Market, by Region, 2022-2032 (USD Billion)
6.10 Soliqua
6.10.1 Competitor Glp-1 Products Threat to Growth
Table 70 Soliqua Market, by Region, 2022-2032 (USD Billion)
6.11 Zepbound
6.11.1 Strong Revenue Growth to Ensure Continued Presence
Table 71 Zepbound Market, by Region, 2022-2032 (USD Billion)
Table 72 North America: Zepbound Market, by Country, 2022-2032 (USD Billion)
Table 73 Europe: Zepbound Market, by Country, 2022-2032 (USD Billion)
Table 74 Asia-Pacific: Zepbound Market, by Country, 2022-2032 (USD Billion)
Table 75 Latin America: Zepbound Market, by Country, 2022-2032 (USD Billion)
Table 76 Middle East: Zepbound Market, by Region, 2022-2032 (USD Billion)
Table 77 Gcc Countries: Zepbound Market, by Country, 2022-2032 (USD Billion)
6.12 Bydureon
6.12.1 Competitor Products to Affect Market Growth
Table 78 Bydureon Market, by Region, 2022-2032 (USD Billion)
6.13 Other Products
Table 79 Other Products Market, by Region, 2022-2032 (USD Billion)

7 Glp-1 Analogues Market, by Format

7.1 Introductions
Table 80 Glp-1 Analogues Industry, by Format, 2022-2032 (USD Billion)
7.2 Single Dose Glp-1 Analogues
7.2.1 High Adoption due to Ease of Administration to Support Growth
Table 81 Market, by Region, 2022-2032 (USD Billion)
Table 82 North America: Market, by Country, 2022-2032 (USD Billion)
Table 83 Europe: Market, by Country, 2022-2032 (USD Billion)
Table 84 Asia-Pacific: Market, by Country, 2022-2032 (USD Billion)
Table 85 Latin America: Market, by Country, 2022-2032 (USD Billion)
Table 86 Middle East: Market, by Country, 2022-2032 (USD Billion)
Table 87 Gcc Countries: Market, by Country, 2022-2032 (USD Billion)
7.3 Multi-Dose Glp-1 Analogues
7.3.1 Low Cost to Attract Larger Adoption
Table 88 Market, by Region, 2022-2032 (USD Billion)
Table 89 North America: Market, by Country, 2022-2032 (USD Billion)
Table 90 Europe: Market, by Country, 2022-2032 (USD Billion)
Table 91 Asia-Pacific: Market, by Country, 2022-2032 (USD Billion)
Table 92 Latin America: Market, by Country, 2022-2032 (USD Billion)
Table 93 Middle East: Market, by Country, 2022-2032 (USD Billion)
Table 94 Gcc Countries: Market, by Country, 2022-2032 (USD Billion)
7.4 Tablets
7.4.1 Development of High-Potency Glp-1S to Support Market Growth
Table 95 Glp-1 Analogue Tablets Market, by Region, 2022-2032 (USD Billion)
Table 96 North America: Glp-1 Analogue Tablets Market, by Country, 2022-2032 (USD Billion)
Table 97 Europe: Glp-1 Analogue Tablets Market, by Country, 2022-2032 (USD Billion)
Table 98 Asia-Pacific: Glp-1 Analogue Tablets Market, by Country, 2022-2032 (USD Billion)
Table 99 Latin America: Glp-1 Analogue Tablets Market, by Country, 2022-2032 (USD Billion)
Table 100 Middle East: Glp-1 Analogue Tablets Market, by Country, 2022-2032 (USD Billion)
Table 101 Gcc Countries: Glp-1 Analogue Tablets Market, by Country, 2022-2032 (USD Billion)

8 Glp-1 Analogues Market, by Route of Administration

8.1 Introduction
Table 102 Glp-1 Analogues Industry, by Route of Administration, 2022-2032 (USD Billion)
8.2 Subcutaneous Administration Glp-1 Analogues
Table 103 Market, by Type, 2022-2032 (USD Billion)
Table 104 Market, by Region, 2022-2032 (USD Billion)
Table 105 North America: Market, by Country, 2022-2032 (USD Million)
Table 106 Europe: Market, by Country, 2022-2032 (USD Billion)
Table 107 Asia-Pacific: Market, by Country, 2022-2032 (USD Billion)
Table 108 Latin America: Market, by Country, 2022-2032 (USD Billion)
Table 109 Middle East: Market, by Region, 2022-2032 (USD Billion)
Table 110 Gcc Countries: Market, by Country, 2022-2032 (USD Billion)
8.2.1 Pen Injectors
8.2.1.1 Ease of Monitoring to Support Adoption
Table 111 Glp-1 Analogue Pen Injectors Market, by Region, 2022-2032 (USD Billion)
Table 112 North America: Glp-1 Analogue Pen Injectors Market, by Country, 2022-2032 (USD Billion)
Table 113 Europe: Glp-1 Analogue Pen Injectors Market, by Country, 2022-2032 (USD Billion)
Table 114 Asia-Pacific: Glp-1 Analogue Pen Injectors Market, by Country, 2022-2032 (USD Billion)
Table 115 Latin America: Glp-1 Analogue Pen Injectors Market, by Country, 2022-2032 (USD Billion)
Table 116 Middle East: Glp-1 Analogue Pen Injectors Market, by Region, 2022-2032 (USD Billion)
Table 117 Gcc Countries: Glp-1 Analogue Pen Injectors Market, by Country, 2022-2032 (USD Billion)
8.2.2 Autoinjectors
8.2.2.1 Advantages Offered Over Pen Injectors to Support Adoption
Table 118 Glp-1 Analogue Autoinjectors Market, by Region, 2022-2032 (USD Billion)
Table 119 North America: Glp-1 Analogue Autoinjectors Market, by Country, 2022-2032 (USD Billion)
Table 120 Europe: Glp-1 Analogue Autoinjectors Market, by Country, 2022-2032 (USD Billion)
Table 121 Asia-Pacific: Glp-1 Analogue Autoinjectors Market, by Country, 2022-2032 (USD Billion)
Table 122 Latin America: Glp-1 Analogue Autoinjectors Market, by Country, 2022-2032 (USD Billion)
Table 123 Middle East: Glp-1 Analogue Autoinjectors Market, by Region, 2022-2032 (USD Billion)
Table 124 Gcc Countries: Glp-1 Analogue Autoinjectors Market, by Country, 2022-2032 (USD Billion)
8.3 Oral Administration Glp-1 Analogues
8.3.1 Elimination of Needle Phobia and Ease of Use to Drive Compliance
Table 125 Market, by Region, 2022-2032 (USD Billion)
Table 126 North America: Market, by Country, 2022-2032 (USD Billion)
Table 127 Europe: Market, by Country, 2022-2032 (USD Billion)
Table 128 Asia-Pacific: Market, by Country, 2022-2032 (USD Billion)
Table 129 Latin America: Market, by Country, 2022-2032 (USD Billion)
Table 130 Middle East: Market, by Region, 2022-2032 (USD Million)
Table 131 Gcc Countries: Market, by Country, 2022-2032 (USD Billion)

9 Glp-1 Analogues Market, by Indication

9.1 Introduction
Table 132 Glp-1 Analogues Industry, by Indication, 2022-2032 (USD Billion)
9.2 Diabetes
9.2.1 High Efficacy to Support Market Growth
Table 133 Market for Diabetes, by Region, 2022-2032 (USD Billion)
Table 134 North America: Market for Diabetes, by Country, 2022-2032 (USD Billion)
Table 135 Europe: Market for Diabetes, by Country, 2022-2032 (USD Billion)
Table 136 Asia-Pacific: Market for Diabetes, by Country, 2022-2032 (USD Billion)
Table 137 Latin America: Market for Diabetes, by Country, 2022-2032 (USD Billion)
Table 138 Middle East: Market for Diabetes, by Region, 2022-2032 (USD Billion)
Table 139 Gcc Countries: Market for Diabetes, by Country, 2022-2032 (USD Billion)
9.3 Obesity
9.3.1 Increasing Demand and Pipeline Focus on Anti-Obesity Glp-1S to Drive Market
Table 140 Market for Obesity, by Region, 2022-2032 (USD Billion)
Table 141 North America: Market for Obesity, by Country, 2022-2032 (USD Billion)
Table 142 Europe: Market for Obesity, by Country, 2022-2032 (USD Billion)
Table 143 Asia-Pacific: Market for Obesity, by Country, 2022-2032 (USD Billion)
Table 144 Latin America: Market for Obesity, by Country, 2022-2032 (USD Billion)
Table 145 Middle East: Market for Obesity, by Region, 2022-2032 (USD Billion)
Table 146 Gcc Countries: Market for Obesity, by Country, 2022-2032 (USD Billion)
9.4 Other Indications
Table 147 Market for Other Indications, by Region, 2022-2032 (USD Billion)
Table 148 North America: Market for Other Indications, by Country, 2022-2032 (USD Billion)
Table 149 Europe: Market for Other Indications, by Country, 2022-2032 (USD Billion)
Table 150 Asia-Pacific: Market for Other Indications, by Country, 2022-2032 (USD Billion)
Table 151 Latin America: Market for Other Indications, by Country, 2022-2032 (USD Billion)
Table 152 Middle East: Market for Other Indications, by Region, 2022-2032 (USD Billion)

10 Glp-1 Analogues Market, by End-user

10.1 Introductions
Table 153 Glp-1 Analogues Industry, by End-user, 2022-2032 (USD Billion)
10.2 Home Care Settings
10.2.1 Rising Number of Telehealth Companies and Convenience of Home Care to Support Market Growth
Table 154 Market for Home Care Settings, by Region, 2022-2032 (USD Billion)
Table 155 North America: for Home Care Settings, by Country, 2022-2032 (USD Billion)
Table 156 Europe: Market for Home Care Settings, by Country, 2022-2032 (USD Billion)
Table 157 Asia-Pacific: Market for Home Care Settings, by Country, 2022-2032 (USD Billion)
Table 158 Latin America: Market for Home Care Settings, by Country, 2022-2032 (USD Billion)
Table 159 Middle East: Market for Home Care Settings, by Region, 2022-2032 (USD Billion)
Table 160 Gcc Countries: Market for Home Care Settings, by Country, 2022-2032 (USD Billion)
10.3 Long-Term Care Facilities
10.3.1 Growing Geriatric Population and Rising Chronic Disease Incidence to Drive Market
Table 161 Market for Long-Term Care Facilities, by Region, 2022-2032 (USD Billion)
Table 162 North America: Market for Long-Term Care Facilities, by Country, 2022-2032 (USD Billion)
Table 163 Europe: Market for Long-Term Care Facilities, by Country, 2022-2032 (USD Billion)
Table 164 Asia-Pacific: Market for Long-Term Care Facilities, by Country, 2022-2032 (USD Billion)
Table 165 Latin America: Market for Long-Term Care Facilities, by Country, 2022-2032 (USD Billion)
Table 166 Middle East: Market for Long-Term Care Facilities, by Region, 2022-2032 (USD Billion)
Table 167 Gcc Countries: Market for Long-Term Care Facilities, by Country, 2022-2032 (USD Billion)
10.4 Hospitals & Specialty Clinics
10.4.1 Adoption of Glp-1 for Varied Indications to Support Market Growth
Table 168 Market for Hospitals & Specialty Clinics, by Region, 2022-2032 (USD Billion)
Table 169 North America: Market for Hospitals & Specialty Clinics, by Country, 2022-2032 (USD Billion)
Table 170 Europe: Market for Hospitals & Specialty Clinics, by Country, 2022-2032 (USD Billion)
Table 171 Asia-Pacific: Market for Hospitals & Specialty Clinics, by Country, 2022-2032 (USD Billion)
Table 172 Latin America: Market for Hospitals & Specialty Clinics, by Country, 2022-2032 (USD Billion)
Table 173 Middle East: Market for Hospitals & Specialty Clinics, by Region, 2022-2032 (USD Billion)
Table 174 Gcc Countries: Market for Hospitals & Specialty Clinics, by Country, 2022-2032 (USD Billion)

11 Glp-1 Analogues Market, by Region

11.1 Introduction
Table 175 Glp-1 Analogues Industry, by Region, 2022-2032 (USD Billion)
11.2 North America
11.2.1 North America: Recession Impact
Figure 39 North America Glp-1 Analogues Market Snapshot
Table 176 North America: Market, by Product, 2022-2032 (USD Billion)
Table 177 North America: Market, by Format, 2022-2032 (USD Billion)
Table 178 North America: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 179 North America: Market, by Type, 2022-2032 (USD Billion)
Table 180 North America: Market, by Indication, 2022-2032 (USD Billion)
Table 181 North America: Market, by End-user, 2022-2032 (USD Billion)
Table 182 North America: Market, by Country, 2022-2032 (USD Billion)
11.2.2 US
11.2.2.1 Strategic Developments by Major Players and R&D Activities to Drive Market
Table 183 US: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 184 US: Market, by Format, 2022-2032 (USD Billion)
Table 185 US: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 186 US: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 187 US: Market, by Indication, 2022-2032 (USD Billion)
Table 188 US: Market, by End-user, 2022-2032 (USD Billion)
11.2.3 Canada
11.2.3.1 Strong Research Infrastructure and Availability of Funding to Support Market Growth
Table 189 Canada: Market, by Product, 2022-2032 (USD Billion)
Table 190 Canada: Market, by Format, 2022-2032 (USD Billion)
Table 191 Canada: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 192 Canada: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 193 Canada: Market, by Indication, 2022-2032 (USD Billion)
Table 194 Canada: Market, by End-user, 2022-2032 (USD Billion)
11.3 Europe
11.3.1 Europe: Recession Impact
Figure 40 Europe: Glp-1 Analogues Market Snapshot
Table 195 Europe: Market, by Product, 2022-2032 (USD Billion)
Table 196 Europe: Market, by Format, 2022-2032 (USD Billion)
Table 197 Europe: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 198 Europe: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 199 Europe: Market, by Indication, 2022-2032 (USD Billion)
Table 200 Europe: Market, by End-user, 2022-2032 (USD Billion)
Table 201 Europe: Market, by Country, 2022-2032 (USD Billion)
11.3.2 Germany
11.3.2.1 Improving Accessibility to Support Market Growth in Germany
Table 202 Germany: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 203 Germany: Market, by Format, 2022-2032 (USD Billion)
Table 204 Germany: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 205 Germany: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 206 Germany: Market, by Indication, 2022-2032 (USD Billion)
Table 207 Germany: Market, by End-user, 2022-2032 (USD Billion)
11.3.3 UK
11.3.3.1 Increasing Research to Evaluate Efficacy and Potential of Glp-1 Analogues to Support Market Growth
Table 208 UK: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 209 UK: Market, by Format, 2022-2032 (USD Billion)
Table 210 UK: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 211 UK: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 212 UK: Market, by Indication, 2022-2032 (USD Billion)
Table 213 UK: Market, by End-user, 2022-2032 (USD Billion)
11.3.4 France
11.3.4.1 Growing Awareness to Propel Market Growth
Table 214 France: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 215 France: Market, by Format, 2022-2032 (USD Billion)
Table 216 France: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 217 France: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 218 France: Market, by Indication, 2022-2032 (USD Billion)
Table 219 France: Market, by End-user, 2022-2032 (USD Billion)
11.3.5 Italy
11.3.5.1 Presence of Major Pharmaceutical and Biotechnology Companies to Drive Market
Table 220 Italy: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 221 Italy: Market, by Format, 2022-2032 (USD Billion)
Table 222 Italy: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 223 Italy: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 224 Italy: Market, by Indication, 2022-2032 (USD Billion)
Table 225 Italy: Market, by End-user, 2022-2032 (USD Billion)
11.3.6 Spain
11.3.6.1 Favorable Initiatives for Research to Drive Market
Table 226 Spain: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 227 Spain: Market, by Format, 2022-2032 (USD Billion)
Table 228 Spain: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 229 Spain: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 230 Spain: Market, by Indication, 2022-2032 (USD Billion)
Table 231 Spain: Market, by End-user, 2022-2032 (USD Billion)
11.3.7 Netherlands
11.3.7.1 Growing Awareness and Strong Focus on Pharmaceutical R&D to Support Market Growth
Table 232 Netherlands: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 233 Netherlands: Market, by Format, 2022-2032 (USD Billion)
Table 234 Netherlands: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 235 Netherlands: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 236 Netherlands: Market, by Indication, 2022-2032 (USD Billion)
Table 237 Netherlands: Market, by End-user, 2022-2032 (USD Billion)
11.3.8 Rest of Europe
Table 238 Rest of Europe: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 239 Rest of Europe: Market, by Format, 2022-2032 (USD Billion)
Table 240 Rest of Europe: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 241 Rest of Europe: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 242 Rest of Europe: Market, by Indication, 2022-2032 (USD Billion)
Table 243 Rest of Europe: Market, by End-user, 2022-2032 (USD Billion)
11.4 Asia-Pacific
11.4.1 Asia-Pacific: Recession Impact
Table 244 Asia-Pacific: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 245 Asia-Pacific: Market, by Format, 2022-2032 (USD Billion)
Table 246 Asia-Pacific: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 247 Asia-Pacific: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 248 Asia-Pacific: Market, by Indication, 2022-2032 (USD Billion)
Table 249 Asia-Pacific: Market, by End-user, 2022-2032 (USD Billion)
Table 250 Asia-Pacific: Market, by Country, 2022-2032 (USD Billion)
11.4.2 China
11.4.2.1 Expansion of Major Biotechnology and Pharmaceutical Companies in China to Drive Market
Table 251 China: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 252 China: Market, by Format, 2022-2032 (USD Billion)
Table 253 China: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 254 China: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 255 China: Market, by Indication, 2022-2032 (USD Billion)
Table 256 China: Market, by End-user, 2022-2032 (USD Billion)
11.4.3 Japan
11.4.3.1 Growing Availability of Prominent Glp-1 Drugs to Drive Market
Table 257 Japan: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 258 Japan: Market, by Format, 2022-2032 (USD Billion)
Table 259 Japan: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 260 Japan: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 261 Japan: Market, by Indication, 2022-2032 (USD Billion)
Table 262 Japan: Market, by End-user, 2022-2032 (USD Billion)
11.4.4 India
11.4.4.1 Strong Initiatives to Develop Cost-Effective and Patient-Friendly Medications to Aid Market Growth
Table 263 India: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 264 India: Market, by Format, 2022-2032 (USD Billion)
Table 265 India: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 266 India: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 267 India: Market, by Indication, 2022-2032 (USD Billion)
Table 268 India: Market, by End-user, 2022-2032 (USD Billion)
11.4.5 Australia
11.4.5.1 Access to Glp-1 Drugs and Government Support to Drive Market
Table 269 Australia: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 270 Australia: Market, by Format, 2022-2032 (USD Billion)
Table 271 Australia: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 272 Australia: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 273 Australia: Market, by Indication, 2022-2032 (USD Billion)
Table 274 Australia: Market, by End-user, 2022-2032 (USD Billion)
11.4.6 South Korea
11.4.6.1 Collaborations in Obesity Drugs to Propel Market Growth
Table 275 South Korea: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 276 South Korea: Market, by Format, 2022-2032 (USD Billion)
Table 277 South Korea: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 278 South Korea: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 279 South Korea: Market, by Indication, 2022-2032 (USD Billion)
Table 280 South Korea: Market, by End-user, 2022-2032 (USD Billion)
11.4.7 Rest of Asia-Pacific
Table 281 Rest of Asia-Pacific: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 282 Rest of Asia-Pacific: Market, by Format, 2022-2032 (USD Billion)
Table 283 Rest of Asia-Pacific: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 284 Rest of Asia-Pacific: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 285 Rest of Asia-Pacific: Market, by Indication, 2022-2032 (USD Billion)
Table 286 Rest of Asia-Pacific: Market, by End-user, 2022-2032 (USD Billion)
11.5 Latin America
11.5.1 Latin America: Recession Impact
Table 287 Latin America: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 288 Latin America: Market, by Format, 2022-2032 (USD Billion)
Table 289 Latin America: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 290 Latin America: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 291 Latin America: Glp-1 Analogues Market, by Indication, 2022-2032 (USD Billion)
Table 292 Latin America: Market, by End-user, 2022-2032 (USD Billion)
Table 293 Latin America: Market, by Country, 2022-2032 (USD Billion)
11.5.2 Brazil
11.5.2.1 Brazil to Hold Largest Market Share in Latin America
Table 294 Brazil: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 295 Brazil: Market, by Format, 2022-2032 (USD Billion)
Table 296 Brazil: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 297 Brazil: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 298 Brazil: Market, by Indication, 2022-2032 (USD Billion)
Table 299 Brazil: Market, by End-user, 2022-2032 (USD Billion)
11.5.3 Mexico
11.5.3.1 Growing Diabetes and Obesity Cases to Support Market Growth
Table 300 Mexico: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 301 Mexico: Market, by Format, 2022-2032 (USD Billion)
Table 302 Mexico: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 303 Mexico: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 304 Mexico: Market, by Indication, 2022-2032 (USD Billion)
Table 305 Mexico: Market, by End-user, 2022-2032 (USD Billion)
11.5.4 Rest of Latin America
Table 306 Rest of Latin America: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 307 Rest of Latin America: Market, by Format, 2022-2032 (USD Billion)
Table 308 Rest of Latin America: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 309 Rest of Latin America: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 310 Rest of Latin America: Market, by Indication, 2022-2032 (USD Billion)
Table 311 Rest of Latin America: Market, by End-user, 2022-2032 (USD Billion)
11.6 Middle East
11.6.1 Middle East: Recession Impact
Table 312 Middle East: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 313 Middle East: Market, by Format, 2022-2032 (USD Billion)
Table 314 Middle East: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 315 Middle East: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 316 Middle East: Market, by Indication, 2022-2032 (USD Billion)
Table 317 Middle East: Market, by End-user, 2022-2032 (USD Billion)
Table 318 Middle East: Market, by Region, 2022-2032 (USD Billion)
11.6.2 Gcc Countries
Table 319 Gcc Countries: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 320 Gcc Countries: Market, by Format, 2022-2032 (USD Billion)
Table 321 Gcc Countries: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 322 Gcc Countries: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 323 Gcc Countries: Market, by Indication, 2022-2032 (USD Billion)
Table 324 Gcc Countries: Market, by End-user, 2022-2032 (USD Billion)
Table 325 Gcc Countries: Market, by Country, 2022-2032 (USD Billion)
11.6.2.1 Saudi Arabia
11.6.2.1.1 Growing Availability of Glp-1 Drugs to Support Market Growth
Table 326 Saudi Arabia: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 327 Saudi Arabia: Market, by Format, 2022-2032 (USD Billion)
Table 328 Saudi Arabia: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 329 Saudi Arabia: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 330 Saudi Arabia: Market, by Indication, 2022-2032 (USD Billion)
Table 331 Saudi Arabia: Market, by End-user, 2022-2032 (USD Billion)
11.6.2.2 UAE
11.6.2.2.1 Growing Regulatory Approvals for Glp-1 Drugs to Support Market Growth
Table 332 UAE: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 333 UAE: Market, by Format, 2022-2032 (USD Billion)
Table 334 UAE: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 335 UAE: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 336 UAE: Market, by Indication, 2022-2032 (USD Billion)
Table 337 UAE: Market, by End-user, 2022-2032 (USD Billion)
11.6.2.3 Rest of Gcc Countries
Table 338 Rest of Gcc Countries: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 339 Rest of Gcc Countries: Market, by Format, 2022-2032 (USD Billion)
Table 340 Rest of Gcc Countries: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 341 Rest of Gcc Countries: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 342 Rest of Gcc Countries: Market, by Indication, 2022-2032 (USD Billion)
Table 343 Rest of Gcc Countries: Market, by End-user, 2022-2032 (USD Billion)
11.6.3 Rest of Middle East
Table 344 Rest of Middle East: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 345 Rest of Middle East: Market, by Format, 2022-2032 (USD Billion)
Table 346 Rest of Middle East: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 347 Rest of Middle East: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 348 Rest of Middle East: Market, by Indication, 2022-2032 (USD Billion)
Table 349 Rest of Middle East: Market, by End-user, 2022-2032 (USD Billion)
11.7 Africa
11.7.1 Growing Healthcare and Life Science Industry to Support Growth
11.7.2 Africa: Recession Impact
Table 350 Africa: Glp-1 Analogues Market, by Product, 2022-2032 (USD Billion)
Table 351 Africa: Market, by Format, 2022-2032 (USD Billion)
Table 352 Africa: Market, by Route of Administration, 2022-2032 (USD Billion)
Table 353 Africa: Subcutaneously Administered Glp-1 Analogues Market, by Type, 2022-2032 (USD Billion)
Table 354 Africa: Market, by Indication, 2022-2032 (USD Billion)
Table 355 Africa: Market, by End-user, 2022-2032 (USD Billion)

12 Competitive Landscape

12.1 Overview
12.2 Key Player Strategy/Right to Win
12.2.1 Overview of Strategies Adopted by Players in Glp-1 Analogues Market
Table 356 Overview of Strategies Deployed by Key Manufacturing Companies
12.3 Revenue Analysis
Figure 41 Revenue Analysis of Key Players in Glp-1 Analogues Industry, 2021-2023
12.4 Market Share Analysis
Figure 42 Market Share Analysis of Key Players in Market, 2023
Table 357 Glp-1 Analogues Industry: Degree of Competition
12.5 Company Evaluation Matrix: Key Players, 2023
12.5.1 Stars
12.5.2 Emerging Leaders
12.5.3 Pervasive Players
12.5.4 Participants
Figure 43 Glp-1 Analogues Industry: Company Evaluation Matrix (Key Players), 2023
12.6 Company Evaluation Matrix: Players with Products in Pipeline, 2023
12.6.1 Stars
12.6.2 Emerging Leaders
12.6.3 Pervasive Players
12.6.4 Participants
Figure 44 Glp-1 Analogues Market: Company Evaluation Matrix (Players with Products in Pipeline), 2023
12.6.5 Company Footprint: Key Players, 2023
12.6.5.1 Company Footprint
Figure 45 Market: Company Footprint (Key Players)
Figure 46 Market: Company Footprint (Players with Products in Pipeline)
12.6.5.2 Format Footprint
Table 358 Market: Format Footprint
12.6.5.3 Route of Administration Footprint
Table 359 Market: Route of Administration Footprint
Table 360 Market: Route of Administration Footprint (Players with Products in Pipeline)
12.6.5.4 Indication Footprint
Table 361 Market: Indication Footprint (Key Players)
Table 362 Market: Indication Footprint (Players with Products in Pipeline)
12.6.5.5 Region Footprint
Table 363 Glp-1 Analogues Industry: Region Footprint (Key Players)
12.7 Company Evaluation Matrix: Startups/SMEs, 2023
12.7.1 Progressive Companies
12.7.2 Responsive Companies
12.7.3 Dynamic Companies
12.7.4 Starting Blocks
Figure 47 Market: Company Evaluation Matrix (Startups/SMEs), 2023
12.7.5 Competitive Benchmarking: Startups/SMEs, 2023
Table 364 Market: Detailed List of Key Start-Ups/SMEs
Table 365 Market: Competitive Benchmarking of Key Emerging Players/Startups
12.8 Valuation & Financial Metrics
12.8.1 Financial Metrics
Figure 48 EV/Ebitda of Key Vendors
12.8.2 Company Valuation
Figure 49 Year-To-Date (Ytd) Price Total Return and 5-Year Stock Beta of Key Vendors
12.9 Brand/Product Comparison
Figure 50 Market: Brand/Product Comparative Analysis (Antidiabetic Glp-1 Analogues)
Figure 51 Market: Brand/Product Comparative Analysis (Anti-Obesity Glp-1 Analogues)
12.1 Competitive Scenario
12.10.1 Product Approvals
Table 366 Glp-1 Analogues Industry: Product Approvals, January 2021-May 2024
12.10.2 Deals
Table 367 Glp-1 Analogues Industry: Deals, January 2021-May 2024
12.10.3 Expansions
Table 368 Glp-1 Analogues Industry: Expansions, January 2021-May 2024
12.10.4 Other Developments
Table 369 Glp-1 Analogues Industry: Other Developments, January 2021-May 2024

13 Company Profiles

13.1 Introduction
(Business Overview, Products Offered, Recent Developments & Analyst's View)*
13.2 Key Players
13.2.1 Novo Nordisk A/S
Table 370 Novo Nordisk A/S: Company Overview
Figure 52 Novo Nordisk A/S: Company Snapshot
Table 371 Novo Nordisk A/S: Products Offered
Table 372 Novo Nordisk A/S: Product Approvals, January 2021-April 2024
Table 373 Novo Nordisk A/S: Expansions, January 2021-April 2024
Table 374 Novo Nordisk A/S: Other Developments, January 2021-April 2024
13.2.2 Eli Lilly and Company
Table 375 Eli Lilly and Company: Company Overview
Figure 53 Eli Lilly and Company: Company Snapshot
Table 376 Eli Lilly and Company: Products Offered
Table 377 Eli Lilly and Company: Product Approvals, January 2021-April 2024
Table 378 Eli Lilly and Company: Deals, January 2021-April 2024
Table 379 Eli Lilly and Company: Expansions, January 2021-April 2024
13.2.3 Sanofi
Table 380 Sanofi: Company Overview
Figure 54 Sanofi: Company Snapshot
Table 381 Sanofi: Products Offered
13.2.4 Astrazeneca
Table 382 Astrazeneca: Company Overview
Figure 55 Astrazeneca: Company Snapshot
Table 383 Astrazeneca: Products Offered
Table 384 Astrazeneca: Product Approvals, January 2021-April 2024
13.2.5 Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
Table 385 Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Company Overview
Figure 56 Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Company Snapshot
Table 386 Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Products Offered
13.2.6 Boehringer Ingelheim International GmbH
Table 387 Boehringer Ingelheim International GmbH: Company Overview
Figure 57 Boehringer Ingelheim International GmbH: Company Snapshot
Table 388 Boehringer Ingelheim International GmbH: Products in Pipeline
Table 389 Boehringer Ingelheim International GmbH: Deals, January 2021-April 2024
Table 390 Boehringer Ingelheim International GmbH: Other Developments, January 2021-April 2024
13.2.7 Innovent
Table 391 Innovent: Company Overview
Figure 58 Innovent: Company Snapshot
Table 392 Innovent: Products in Pipeline
Table 393 Innovent: Other Developments, January 2021-April 2024
13.2.8 Paige Biopharmaceutical (Suzhou) Co. Ltd.
Table 394 Paige Biopharmaceutical (Suzhou) Co. Ltd.: Company Overview
Table 395 Paige Biopharmaceutical (Suzhou) Co. Ltd.: Products in Pipeline
13.2.9 Sciwind Biosciences Co. Ltd.
Table 396 Sciwind Biosciences Co. Ltd.: Company Overview
Table 397 Sciwind Biosciences Co. Ltd.: Products in Pipeline
Table 398 Sciwind Biosciences Co. Ltd.: Deals, January 2021-April 2024
Table 399 Sciwind Biosciences Co. Ltd.: Other Developments, January 2021-April 2024
13.2.10 Zealand Pharma A/S
Table 400 Zealand Pharma A/S: Company Overview
Figure 59 Zealand Pharma A/S: Company Snapshot
Table 401 Zealand Pharma A/S: Products in Pipeline
Table 402 Zealand Pharma A/S: Deals, January 2021-April 2024
Table 403 Zealand Pharma A/S: Other Developments, January 2021-April 2024
13.2.11 Beijing Dongfang Baitai Biotechnology Co. Ltd (Eastern Biotech)
Table 404 Beijing Dongfang Baitai Biotechnology: Company Overview
Table 405 Beijing Dongfang Baitai Biotechnology: Products in Pipeline
*Details on Business Overview, Products Offered, Recent Developments & Analyst's View Might Not be Captured in Case of Unlisted Companies.
13.3 Other Players
13.3.1 Sun Pharmaceutical Industries Ltd.
13.3.2 Vtv Therapeutics
13.3.3 Terns Pharmaceuticals, Inc.
13.3.4 Altimmune
13.3.5 Scohia Pharma, Inc.
13.3.6 Structure Therapeutics
13.3.7 Neurobo Pharmaceuticals, Inc.
13.3.8 I2O Therapeutics, Inc.
13.3.9 Amgen Inc.
13.3.10 Pfizer Inc.
13.3.11 Merck & Co. Inc.
13.3.12 Hanmi Pharm Co. Ltd.
13.3.13 Viking Therapeutics
13.3.14 Jiangsu Hengrui Pharmaceuticals Co. Ltd.

14 Appendix

14.1 Discussion Guide
14.2 Knowledgestore: The Subscription Portal
14.3 Customization Options

Companies Mentioned

Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Astrazeneca
Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
Boehringer Ingelheim International GmbH
Innovent
Paige Biopharmaceutical (Suzhou) Co. Ltd.
Sciwind Biosciences Co. Ltd.
Zealand Pharma A/S
Beijing Dongfang Baitai Biotechnology Co. Ltd (Eastern Biotech)
Sun Pharmaceutical Industries Ltd.
Vtv Therapeutics
Terns Pharmaceuticals, Inc.
Altimmune
Scohia Pharma, Inc.
Structure Therapeutics
Neurobo Pharmaceuticals, Inc.
I2O Therapeutics, Inc.
Amgen Inc.
Pfizer Inc.
Merck & Co. Inc.
Hanmi Pharm Co. Ltd.
Viking Therapeutics
Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Table Information

Report Attribute	Details
No. of Pages	316
Published	July 2024
Forecast Period	2024 - 2032
Estimated Market Value ( USD ) in 2024	$ 47.4 Billion
Forecasted Market Value ( USD ) by 2032	$ 471.1 Billion
Compound Annual Growth Rate	33.2%
Regions Covered	Global
No. of Companies Mentioned	25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4782EUR$4,950USD£3,968GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6424EUR$6,650USD£5,330GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7873EUR$8,150USD£6,533GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9660EUR$10,000USD£8,015GBP

GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Forecast to 2032

By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market

By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market

North America: accounted for the largest share of the GLP-1 Analogues market

Europe: The second-largest region in the GLP-1 Analogues market

The primary interviews conducted for this report can be categorized as follows:

Prominent Players

Research Coverage

Key Benefits of Buying the Report

The report provides insights on the following pointers

Table of Contents

Companies Mentioned

Table Information

By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market

By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market

North America: accounted for the largest share of the GLP-1 Analogues market

Europe: The second-largest region in the GLP-1 Analogues market

The primary interviews conducted for this report can be categorized as follows:

Prominent Players

Research Coverage

Key Benefits of Buying the Report

The report provides insights on the following pointers

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Anti-Obesity Drugs Market Report and Forecast 2024-2032

Europe Anti-Obesity Drugs Market Report and Forecast 2024-2032

Obesity - Pipeline Insight, 2024

Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: Seven-Market Drug Forecast and Market Analysis

Wegovy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029